The brain endothelial large neutral amino acid car rier (L-system) is well suited for facilitated drug transport to the brain because of its high transport capacity and relatively broad structural substrate tolerance. The authors have examined the potential of this transporter for central nervous system (CNS) delivery of a new family of compounds derived from the large neutral amino acid phenylglycine. These compounds are highly selective for specific isoforms of metabotropic glutamate re ceptors (mGluRs) but will only become effective therapeutics for CNS diseases such as ischemic disorders, stroke, and epi lepsy if they can effectively cross the blood-brain barrier. Us ing the immortalized rat brain endothelial cell line RBE4 as in vitro blood-brain barrier model, the authors have studied the interaction of phenyl glycine and selected derivatives with the L-system-mediated transport of L-[ 3 H]-histidine. The transport of L-histidine was characteristic of the L-system in vivo with the following kinetic parameters: Km 135 ± 18 ILmol!L, V max 15.3 ± 1.13 nmol/min/mg protein, and K D 2.38 ± 0.84 ILL/min/mg protein. The affinities of the L-system for phenyl glycine and the derivatives investigated increased in the order S-4-carboxy phenylglycine (Ki = 16 mmol/L) < R-phenylglycine (2.2 mmol/L) < S-3-hydroxy-phenylglycine (48 ILmollL) < S-Neurologic disorders such as ischemia, stroke, trauma, epilepsy, and schizophrenia, but also dementia, Parkin son's disease, and Alzheimer's disease have been asso ciated with amino acid excitotoxicity (Lipton and Rosen-Abbreviations: BBB. blood-brain barrier; CNS, central nervous sys tem; HPLC, high-performance liquid chromatography; mGluRs, metabotropic glutamate receptors; RBE4, immortalized rat brain endo thelial cell line.
phenylglycine (34 ILmol/L), suggesting that a negative charge at the side chain or R-configuration is detrimental for carrier recognition, whereas neutral side chain substituents are well tolerated. The authors have further shown (1) that the mode of interaction with the L-system of S-phenylglycine and S-3hydroxy-phenylglycine is competitive, and (2) that the trans porter carries these two agents into the cell as shown by high performance liquid chromatography (HPLC) analysis of the RBE4 cell contents. The study provides the first evidence for the potential of S-phenylg1y cine derivatives for carrier mediated delivery to the CNS and outlines the substrate speci ficity of the L-system at the blood-brain barrier for this class of mGluR ligands. As the affinities of S-phenylglycine and S-3hydroxy-phenylglycine for the L-system carrier are even higher than those of some natural substrates, these agents should ef ficiently enter CNS via this route. Possible strategies for a synergistic optimization of phenylglycine-derived therapeutics with respect to desired activity at the CNS target combined with carrier-mediated delivery to overcome the blood-brain barrier are discussed. Key Words: Phenylglycine derivatives Metabotropic glutamate receptors-L-system amino acid trans porter-Drug delivery-Blood-brain barrier-In vitro. berg, 1994) . Consequently, current strategies to prevent the pathologic consequences of excess glutamate are fo cused on antagonists for glutamate receptors (GluRs), in particular those of the N-methyl-D-aspartate group (Boxer and Bigge, 1997) . However, it is now appreciated that use of therapeutic antagonists to ionotropic GluRs may compromise fast excitatory synaptic transmission thereby complicating chronic therapy (Meldrum, 1994) . Therefore, G protein-coupled metabotropic GluRs (mGluRs) that mediate excitatory synaptic transmission only under particular circumstances (Conn and Pin, 1997) are emerging as novel drug targets with the po tential to overcome shortcomings associated with iono tropic GluRs (Knopfel et aI., 1995; Nicoletti et aI., 1996) .
The mGluR family comprises at least eight subtypes, which are grouped into three classes on the basis of sequence similarities, signal transduction mechanisms, and pharmacologic profile of activation (Conn and Pin, 1997) . With respect to their effects on synaptic excitation it is expected that excitotoxicity will be prevented by class I (mGluR 1/5) antagonists, whereas agonists of class II (mGluR 2/3) or class III (mGluR 4/6/7/8) will be neuroprotective (Roberts, 1995) . The discovery of the first definitive ligands of mGluRs which are derivatives of the large neutral amino acid phenylglycine not only improved understanding of the physiologic role of the mGluR SUbtypes but also revealed their involvement in excitotoxicity-induced neuronal degeneration (Beding field et aI., 1995) . Although several subtype-specific agents have been identified, the assessment of their neu roprotective potential is often hampered by insufficient in vivo activity, frequently related to failure to reach the central nervous system (CNS) target receptors (Seki yama et aI., 1996) .
The clinical efficacy of treatments of CNS disorders depends greatly on the brain penetration of the therapeu tic agent which is often poor because of the tightness of the blood-brain barrier (BBB) formed by the endothelial cells lining the cerebral microvasculature (Abbott and Romero, 1996) . Many therapeutic molecules rely on lipid-mediated diffusion to cross the brain endothelium, and, therefore, drug lipidization has been a major strat egy to enhance drug entry into brain. A more specific route into the brain is carrier-mediated drug delivery across the BBB, currently used successfully in Parkin son's patients treated with the large neutral amino acid L-DOPA (Smith, 1996) . This drug utilizes the L-system amino acid transporter at the brain endothelium which exhibits a broad substrate specificity but prefers neutral alpha amino acids with large side chains (Smith et aI., 1987) .
As these molecular characteristics of L-system sub strates are shared by phenyl glycine, we examined the potential of this transport system for carrier-mediated delivery, first of phenylglycine, and second of selected derivatives (Fig. 1 ) at the BBB in vitro. We have as sessed the affinity of these agents for the L-system with respect to stereochemistry and structural changes in the side chain and confirmed carrier-mediated transport by high-performance liquid chromatography (HPLC) analy sis of intracellular drug levels.
The study provides further insight into structure affinity relationships of the L-system amino acid trans porter at the brain endothelium, suggesting that S-stereo isomery and uncharged substituents on the phenyl ring of phenylglycine derivatives are essential structural require ments for efficient transport. Knowledge of substrate tol erance, together with the high transport capacity of the L-system, make this transporter highly suitable for the delivery of therapeutics by combining high affinity for BBB transport and for target receptors within the CNS. 
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METHODS
Cell culture
Immortalized rat brain endothelial cells (RBE4 cell line) were grown on rattail collagen-coated 96-well plates or tissue culture tlasks in medium consisting of Ham's FlO and a-MEM (U, volume/volume) supplemented with 10% fetal calf serum, I ng/mL basic fibroblast growth factor, 300 j.1g/mL Geneticin, and 1 ng/mL glutamine. The medium was changed every other day, and when the cells reached confluence (after =4 days) the amounts of basic fibroblast growth factor and fetal calf serum in the medium were halved. The RBE4 cells were used between passages 40 and 50. Experiments were performed 6 to 7 days after seeding.
Transport kinetics
[3H]-histidine was used as model substrate for the L-system. Self-inhibition of eHj-histidine uptake was assessed by incu bating RBE4 cells with aliquots of the uptake medium (Hank's balanced salt solution ) containing 10 mmollL HEPES, pH 7.4) containing trace amounts of eHj-histidine and C4Cj-sucrose and increasing concentrations of unlabeled L-histidine (9 to 1,200 j.1mollL). The incubation was carried out for I minute at 3rc. This incubation period was shown by time-course studies to be optimal, because uptake was linear with time and the amount of eHj-histidine accumulated within the cells high enough to allow good resolution.
Estimation of inhibition constants
For studying the interaction of S-phenylglycine, R-phenyl glycine, S-4-carboxy-phenylglycine, and S-3-hydroxy-phenyl glycine with the L-system transporter, increasing concentrations (9 to 1,200 j.1mollL) of the compounds were added to the in-cubation medium containing 33 nmollL of [3H]-histidine (0.3 ILCi/well) and e4C]-sucrose (0.04 ILCi/well) to correct for non specific effects such as binding and trapping. The experiments were carried out at 37°C, and the incubation time was 1 minute. In addition, inhibition constants were estimated by adding a fixed concentration of the drug (100 ILmol/L) to increasing concentrations of L-histidine (9 to 1,200 ILmollL).
Intracellular uptake of compounds
RBE4 cells grown to confluence in 6-well plastic plates were exposed to Hank's balanced salt solution containing 10 mmollL HEPES (pH 7.4) and 6.4 mmollL S-phenylglycine or S-3hydroxy-phenylglycine, respectively, for I minute at 37°C. The uptake of S-phenylglycine and S-3-hydroxy-phenylglycine was also examined in the presence of 10 mmollL L-histidine. The monolayer was thoroughly washed after terminating the uptake experiment and cells lysed in 1 mL methanol per well. The lysate was centrifuged for 5 minutes to remove precipitated protein and the supernatant frozen until HPLC analysis.
High-performance liquid chromatography analysis of intracellular compounds
Because S-phenylglycine, S-3-hydroxy-phenylglycine, and L-histidine are all a-amino acids, a previously developed HPLC protocol for detection of free primary amino acids in biologic fluids was used (Begley et aI., 1994) . The analysis was per formed using a two-buffer HPLC system and fluorimetric de tection by precolumn derivatization of primary amino acids with o-phthaldialdehyde/!3-mercaptoethanol.
The HPLC used (A) 0.1 mollL sodium acetate buffer con taining 5% tetrahydrofuran, adjusted to pH 7.2 with glacial acetic acid, and (B) methanol containing 5% tetrahydrofuran. Separation was performed on a 50x 4.6-mm inner diameter column of Spherisorb 5 octadecylsilyl (ODS) preceded by a guard column 10x 3.0-mm 10 5 ODS at a flow rate of 1.5 mL/min at 43°C.
Free primary amino acids (including the compounds in ques tion) were derivatized to their fluorescent isoindoles by allow ing aliquots (10 ILL) of deproteinized cell lysate and 5 ILL of fluoraldehyde (Pierce) to react for I minute at room tempera ture. The reaction was stopped by adding 100 ILL of starting buffer (A).
Aliquots (20 ILL) of the reaction mixture were injected onto the column and separated with a linear gradient from A:B (90: 10, vol/vol) to 100% B within l3 minutes. Fluorescence was detected with a fluoromonitor (excitation: 330 nm; emis sion: 450 nm) and chromatograms were computed using OAT A SYSTEM MT2 software (Kontron Instruments).
S-phenylglycine, S-hydroxy-phenylglycine, and L-histidine peaks were identified using (1) 100 ILmollL standard solutions of the respective compound and (2) by spiking cell lysates of untreated RBE4 cells.
Liquid scintillation counting and protein assay
Aliquots (100 fLL) of the cell lysate were mixed with I mL of isopropanol and 4 mL of scintillation cocktail (Cocktail-T). The radioactivity was determined by liquid scintillation spec trometry (TRICARB 1600TR, Packard) using a quench correc tion optimized for [3H]/e4C] dual labels. Background activity was determined by measuring the radioactivity of an equivalent volume of Triton X -100 alone.
The protein content of the cell lysates was measured using the BCA protein assay kit and compared to bovine serum al bumin protein standards. The absorbance of the samples was measured using a microplate reader (MR 500, Dynatech) with J Cereb Blood Flow Metab, Vol. 20, No. /, 2000 Triton X -100 as the reference sample. The protein content in a 96-well plate at confluency was ",10 ILg per well.
Data analysis and statistics
Cellular accumulation of the tracers has been calculated as distribution volume (V d' ILL/mg protein) and was expressed as a ratio of the cellular radioactivity per milligram protein over the radioactivity in the uptake medium per microliter of uptake medium. Distribution volumes for [3H]-histidine were cor rected for nonspecific binding and surface trapping by subtract ing the respective Vd values for e4C]-sucrose, a nonpermeant extracellular marker.
Kinetic parameters of the histidine transport were estimated using nonlinear regression analysis of the concentration (C) dependence of the eH]-histidine influx (J) based on conven tional Michaelis-Menten kinetics, i.e., J = (V max * C)/(Km + C) + K D '" C, with Km as the half-saturation concentration, Vmax the maximum transport capacity, and K D the constant of passive diffusion. Eadie-Hofstee plots (J versus J/C) were used to derive estimates of the kinetic parameters required for the nonlinear regression analysis and to assess the number of trans port systems involved.
The interaction of phenylglycine derivatives with the L system was examined by measuring the effect of increasing concentrations (9 to 1,200 ILmol/L) of the respective compound on [3Hl-histidine uptake by RBE4 cells. Inhibition constants (K,) were estimated by adding a fixed concentration of the putative inhibitor ([i] = 100 ILmollL) to increasing concentra tions of L-histidine and measurement of the unidirectional in flux of eHl-histidine. The resulting apparent transport affinity (Kapp) was used to calculate K; according to K; = (Km * [i])/(Kapp -Km). Lineweaver-Burk plots (IIJ versus 1IC) were used to distinguish between competitive and noncompetitive modes of inhibition.
All results are expressed as means ± SO, and significant differences were calculated using two-tailed Student's t test or ANOV A followed by Tukey's protected t test. Kinetic param eters of the eH]-histidine transport are given with standard errors.
Materials
Tissue culture plastics were purchased from Falcon and cul ture media and supplements from Gibco. All other chemicals were from Sigma (St. Louis, MO), including e4C]-sucrose (specific activity, 12.6 GBq/mmol). L-eH]-histidine (specific activity, 1.48 TBq/mmol) was purchased from Amersham. The BCA protein assay kit was supplied by Pierce and Cocktail-T by BDH. All HPLC reagents were purchased from Fisons.
RESULTS
The interaction of phenylglycine and its derivatives with the L-system amino acid transporter at the brain endothelium has been studied using L-[ 3 H]-histidine as substrate for the carrier system and the RBE4 cell line as an in vitro model of the BBB.
Transport of L-eHl-histidine in RBE4 cells
The uptake of L-eH]-histidine by RBE4 cells was time-dependent with an initial rate of 5.11 ± 0.098 nmol/ min/mg protein and was significantly inhibited by the L-system substrates L-Ieucine (51 %) and 2-aminobicy clo[2.2.1]-heptanecarboxylic acid (43%) but not by the A-system substrate 2-methyl-amino-isobutyric acid (300 jLmolJL, 5-minute incubation period). There was some inhibition (19%) after incubation of the cells with oua bain (20-minute preincubation, 5-minute incubation pe riod). The transport of L-eH]-histidine decreased with increasing concentrations of L-histidine in the incubation medium, showing 92.2% inhibition at a concentration of 1. 2 mmol/L (data not shown). The unidirectional influx of L-[ 3 H]-histidine into the RBE4 cells was saturable, reaching a plateau at concentrations above 300 f-lmollL (Fig. 2) . The transport followed single-carrier Michaelis Menten kinetics with a K m of 135 ± 18 jLmolJL, a V max of 15.3 ± 1. 13 nmoVmin/mg protein, and a K o of 2.38 ± 0.84 JLL/min/mg protein. The linear Eadie-Hofstee plot (inset, Fig. 2 ) suggests that transport of histidine is me diated by one major carrier system.
Effect of phenyl glycine and its derivatives on L-eH]-histidine transport
The uptake of L-eH]-histidine was significantly inhib ited by increasing concentrations of the L-form of phenylglycine (S-phenylglycine) but to a much lesser degree by the D-form (R-phenylglycine) (Fig. 3 ). High concentrations (1.2 mmol/L) of S-phenylglycine led to a virtually complete inhibition of the L-[ 3 H]-histidine transport into RBE4 cells (95%), whereas the same con centration of R-phenylglycine only produced a decrease of 39%. S-4-carboxy-phenylglycine did not affect uptake of L-eH]-histidine by RBE4 cells up to concentrations of 1.2 mmol/L, whereas increasing concentrations of S-3hydroxy-phenylglycine significantly decreased L-eH] histidine uptake resulting in a 95% reduction of the in flux at 1. 2 mmollL (Fig. 3) . The respective inhibition constants Kj were estimated as 34. phenylglycine), 2.21 ± 0. 15 mmollL (R-phenylglycine), 15.9 ± 4.42 mmolJL (S-4-carboxy-phenylglycine), and 48.6 ± 9.67 jLmollL (S-3-hydroxy-phenylglycine).
Mode of interaction of S-phenylglycine and
S-3-hydroxy-phenylglycine with the
L-system transporter
To determine whether S-phenylglycine and S-3-hy droxy phenylglycine act as competitive or noncompeti tive inhibitors of L-eH]-histidine transport in RBE4 cells, the kinetics of L-eH]-histidine transport were also examined in the absence and presence of a fixed concen tration (100 f-lmollL) of the respective compound. The data were plotted as double reciprocal (Lineweaver Burk) plots. As Fig. 4 shows, the regression lines inter cept the ordinate at the same point ( = IN max ) suggest ing a competitive mode of inhibition for both S-phenyl glycine and S-3-hydroxy-phenylglycine.
Effect of histidine on intracellular levels of phenylglycine and its derivatives
Using the HPLC conditions described, S-phenyl glycine, S-3-hydroxy-phenylglycine, and L-histidine were separated with retention times of 8.48, 7.48, and 3.92 minutes, respectively. Variations in the retention times were negligible because of the use of an autosam pIer for sample injection. The cellular uptake of S-phe nylglycine and S-3-hydroxy-phenylglycine was initially investigated after a I-minute exposure of RBE4 cells to concentrations of 500 jLmoIIL of the respective drug in Hank's balanced salt solution. The resulting cellular lev els of the compounds were however below the detection limit of the HPLC system; therefore, higher concentra tions of the drugs in the incubation medium were chosen for subsequent experiments. Figure 5 shows chromato grams representing the cellular amino acid content of RBE4 cells treated with 6.4 mmollL of S-phenylglycine or S-3-hydroxy-phenylglycine alone and in the presence of 10 mmollL L-histidine. Under these conditions the peak areas for both S-phenylglycine and S-3-hydroxy phenylglycine were reduced by 83% and 75%, respec tively. These results show (1) that both compounds are capable of entering RBE4 cells and (2) that the entry of both drugs is blocked by an excess of L-histidine.
DISCUSSION
The present study investigates the interaction of phenylglycine derivatives with the L-system amino acid transporter at the brain endothelium. L-eH]-histidine was chosen as the marker substrate because at pH 7.4 it is transported into the brain predominantly by the L-system (Oldendorf et aI., 1988) . The results confirm that histi dine flux was mediated mainly by a single-carrier system with properties characteristic of the L-system. Although we also observed some effect of ouabain, which is in agreement with the presence of transport by the sodium dependent system N as reported by (Yamakami et aI. J Cereb Blood Flow Metab, Vol. 20, No.1, 2000 1998), the contribution of this carrier to overall histidine flux was only minor (see Fig. 2 ).
The RBE4 cell line is a well-established in vitro model of the BBB derived from rat brain cortical capillary en dothelial cells immortalized with the plasmid pE IA-neo (Abbott et aI., 1995) . The cell line is well characterized with respect to transport systems such as the L-system amino acid carrier (Gomes and Soares-da-Silva, 1999) , nucleoside transporters (Chishty et aI., 1997) , the GLUT -1 glucose transporter (Regina et aI., 1997) , and the drug efflux pump P-glycoprotein (Begley et aI., 1996) . We have demonstrated that the functional char acteristics of the L-system amino acid transporter ex pressed in RBE4 cells closely resemble those found at the BBB in vivo indicating the validity of the model for the present study and the relevance of the findings with respect to drug design for carrier-mediated delivery to the CNS by means of the L-system amino acid trans porter (Reichel et aI., unpublished data). L-histidine (lower traces). The high-performance liquid chroma tography (HPLC) method was essentially as given by Begley et al. (1994) .
The present findings demonstrate that phenylglycine, the parent compound of the congeneric group of specific ligands for mGluRs, is a substrate for carrier-mediated transport at the brain endothelium. The strong dose de pendency of the inhibition of the L-eH]-histidine trans port is indicative of a potent interaction of S-phenyl glycine with the L-system transporter, and the low Ki value of 34 fLmoliL for S-phenylglycine suggests a high transport affinity. The study also agrees with the high stereo selectivity of the L-system (Pardridge, 1983) , be cause the R-form of phenylglycine showed a much weaker interaction with L-[ 3 H]-histidine transport (Ki of 2.2 1 mmollL). Poor substrate properties of R stereoiso mers were also found for N-methyl-D-aspartate receptor antagonists (Li et aI., 1995) and thus should be consid ered when applying compounds as racemates. Because S-phenylglycine was efficiently recognized by the L system carrier at the brain endothelium, we also inves tigated the extent to which the carrier tolerates the addi tion of different functional groups to the phenyl side chain. Presence of a carboxylic acid group on the phenyl ring (S-4-carboxy-phenylglycine) resulted in complete loss of interaction with the L-eHJ-histidine transport, with the respective Ki value being as high as 16 mmol/L. By contrast, the addition of a hydroxyl group to the phe nyl ring (S-3-hydroxy-phenylglycine) only slightly di minished the interaction of S-phenylg1ycine with the L-eH]-histidine transport with a K i value of 49 fLmollL as compared to 34 fLmollL for S-phenylglycine.
The results further suggest that the interaction of S phenylglycine and S-3-hydroxy-phenylglycine with the L-system transporter is competitive. The comparatively low inhibition constants which are in the lower range of the Km values of natural substrates for the L-system transporter at the BBB in situ (10 to 900 fLmollL) (Smith et aI., 1987) suggest a high affinity for the substrate binding site of the transporter. This is not unexpected, because these two compounds differ only by a single CH2 group from phenylalanine and tyrosine, two natural substrates of the L-system carrier with relatively high affinity: Km = 11 and 64 fLmollL, respectively, at the brain endothelium (Smith et aI., 1987) . High-per formance liquid chromatography analysis of RBE4 cell contents confirmed that both compounds indeed enter RBE4 cells by means of the L-system transporter, inas much as their uptake was abolished by an excess of L-histidine. The low intracellular content of S-phenyl glycine and S-3-hydroxy-phenylglycine when the trans porter was inhibited also suggests that entry by simple diffusion is negligible, which is in agreement with the poor lipophilicity of the compounds, e.g., S-phenylgly cine has an octanol/water partition coefficient, log P oct of -1.70 (Hansch and Leo, 1979) .
The findings agree with the proposed structural re quirements for affinity for the L-system transporter (Smith, 1996) , i.e., the carrier prefers a-amino acids with neutral side chains. Polar substituents at the side chain, although reducing the affinity for the transporter, are tolerated when they are uncharged at physiologic pH (e.g., hydroxyl groups). The positive relationship be tween the affinity for the L-system transporter and the side chain lipophilicity of the substrate (Smith et aI., 1987) suggests that the substrate binding site of the trans porter is close to or buried within the plasma membrane, a hypothesis which may also explain why charged a-amino acids (e.g., S-4-carboxy-phenylglycine) do not interact with the carrier.
The derivatives examined in the present study are rep resentative of the phenylglycine family of mGluR li gands, mainly varying in side chain substitutions by hy droxyl, carboxylic acid, and methyl groups (Watkins and Collingridge, 1994) . The results therefore permit some more general conclusions concerning the tolerance of the L-system carrier for phenylglycine derivatives: (1) Phe nylglycine derivatives with carboxylic acid groups will be poor L-system substrates as demonstrated for S-4carboxy-phenylglycine, whereas phosphonic acid groups, e.g., might be less detrimental because of lower acidity.
(2) Phenylglycine derivatives with hydroxyl groups will be efficiently transported by the carrier, with the transport affinity decreasing with the number of hy droxy groups, e.g., S-phenylglycine > S-3H-phenylgly cine or Phe > Tyr > L-DOPA (Smith et aI., 1987) . (3) Phenylglycine derivatives with methyl or ethyl groups at the a-carbon atom will not be tolerated by the L-system transporter (Matthews and Zand, 1977) . By contrast, ad dition of alkyl groups to the phenyl ring will increase side chain lipophilicity and thereby improve the affinity for the L-system transporter.
The present findings indicate that phenylglycine de rivatives can use the L-system transporter at the BBB to gain access to the CNS when the compound is in the S-stereoisoform and carries uncharged substituents on the phenyl ring. To translate this knowledge into the design of neuroprotective drugs, a synergistic optimiza tion of both affinity for mGluRs within the CNS and for the L-system at the BBB could be attempted to overcome the often observed lack of in vivo efficacy of mGluR ligands (Boxer and Bigge, 1997) . Because not only sub strate recognition by the L-system transporter but also the agonist/antagonist profile at mGluRs depends on the side chain substituents of phenylglycine derivatives (Seki yama et aI., 1996) , the synergistic optimization of the nature, number, and relative position of the substituents with respect to both beneficial CNS target activity and efficient BBB transport appears a very promising way forward in the search for orally active mGluR agents. Recently, some orally active mGluR antagonists have been reported (Toms et aI., 1996; Monn et aI., 1997; Gasparini et aI., 1999) , although the mechanism of brain entry remains to be elucidated.
In conclusion, the present study outlines the potential of the L-system amino acid transporter at the BBB to carry specific mGluR ligands based on phenylglycine derivatives into the CNS. The study demonstrates the usefulness of in vitro BBB models in identifying struc tural features that contribute to poor CNS penetration and hence lack of in vivo efficacy and suggests a strategy toward a more rational drug design through parallel op timization of CNS target activity and BBB transport ef ficacy.
